Quick Summary
This study observed that people with hypermobile Ehlers-Danlos Syndrome (hEDS), a connective tissue disorder, were nearly three times more likely to develop Long COVID after SARS-CoV-2 infection compared to matched controls, despite similar infection rates. The increased risk was particularly high in people with hEDS who also had other overlapping conditions like POTS, MCAS, or ME/CFS. These are preliminary findings from a large healthcare database and do not yet explain why this association exists.
Why It Matters
For ME/CFS patients and researchers, this study is relevant because it observed ME/CFS as one of several overlapping post-viral conditions in people with hEDS who developed Long COVID. By analogy, the study suggests that connective tissue and autonomic system features may be associated with risk of prolonged post-viral symptoms in complex multimorbid presentations, which may inform screening and integrated care approaches for ME/CFS populations with comorbid hEDS.
Observed Findings
What the study reports it measured.
- Among ~25,000 patients with hEDS identified in a 19-million-patient US cohort, hEDS was associated with approximately three-fold higher odds of Long COVID diagnosis compared to matched controls, despite similar COVID-19 infection rates.
- Within the hEDS group, Long COVID risk was observed to be highest among patients with concurrent autonomic dysfunction (POTS), immune dysregulation (MCAS), or ME/CFS.
- HEDS was associated with higher prevalence of additional chronic conditions including chronic lung disease, autoimmune disease, depression, and cerebrovascular disease.
- A subgroup of patients received hEDS diagnosis only after a COVID-19 or Long COVID diagnosis; this subgroup showed enrichment for multiple comorbidities, particularly POTS and MCAS.
- Estimated prevalence of hEDS in the cohort was approximately 1 in 800, higher than previously estimated.
Inferred Conclusions
What the authors interpret from those results.
- The authors interpret these findings as evidence that hEDS is underdiagnosed in the general population and carries substantially elevated risk of Long COVID, particularly when combined with autonomic or immune dysregulation.
- The authors suggest that comorbidity burden, rather than hEDS alone, may drive the Long COVID risk observed in this population.
- The authors propose that improved hEDS screening and integrated care pathways are needed to support this complex patient group.
Remaining Questions
- Does the increased Long COVID risk in hEDS reflect pathophysiological vulnerability (e.g. connective tissue or autonomic features predisposing to post-viral illness), detection bias (hEDS patients more likely to be coded with Long COVID), or confounding by healthcare-seeking behaviour and access to diagnosis?
- By what mechanisms, if any, do hEDS and autonomic dysregulation associate with prolonged post-viral symptoms, and are these mechanisms shared across hEDS, Long COVID, and ME/CFS?
- Would earlier hEDS diagnosis or targeted multidisciplinary care reduce Long COVID incidence or severity in this population, and can findings from US electronic health records generalise to other healthcare systems?
What This Study Does Not Prove
This observational study does not establish that hEDS causes Long COVID or ME/CFS, nor does it clarify the causal direction of comorbidity relationships. It does not prove that hEDS screening or treatment pathways will improve Long COVID or ME/CFS outcomes. The findings are specific to patients with recorded hEDS diagnoses in US electronic health records and may not generalise to other healthcare systems or to patients without formal diagnosis.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Pearson, Megan L, Laraway, Bryan J, Elias, Ellen R, Bilousova, Ganna, & Haendel, Melissa A (2026). More common than we thought: Hypermobile Ehlers-Danlos Syndrome, comorbidity burden, and long COVID risk in a national cohort.. PLOS digital health. https://doi.org/10.1371/journal.pdig.0001707
BibTeX
@article{mecfsatlas-pearson-2026-more-common,
author = {Pearson, Megan L and Laraway, Bryan J and Elias, Ellen R and Bilousova, Ganna and Haendel, Melissa A},
title = {More common than we thought: Hypermobile Ehlers-Danlos Syndrome, comorbidity burden, and long COVID risk in a national cohort.},
journal = {PLOS digital health},
year = {2026},
doi = {10.1371/journal.pdig.0001707},
note = {PubMed: 42986813},
url = {https://www.mecfsatlas.com/evidence/pearson-2026-more-common},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/pearson-2026-more-common
Contribute
Private, reviewed by a human. Not a public comment thread.